|
MechanismGABAA receptor agonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 评价 NORA520 片在中国健康成人女性受试者中的安全性、耐受性和药代动力学特征的 I 期临床研究
[Translation] A Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of NORA520 tablets in healthy Chinese adult female subjects
评价 NORA520 片在中国健康成人女性受试者中的安全性和耐受性;评价 NORA520 片在中国健康成人女性受试者中的药代动力学特征。
[Translation] To evaluate the safety and tolerability of NORA520 tablets in healthy Chinese female adult subjects; to evaluate the pharmacokinetic characteristics of NORA520 tablets in healthy Chinese female adult subjects.
100 Clinical Results associated with Gerbera Therapeutics, Inc.
0 Patents (Medical) associated with Gerbera Therapeutics, Inc.
100 Deals associated with Gerbera Therapeutics, Inc.
100 Translational Medicine associated with Gerbera Therapeutics, Inc.